(function(){var loadHandler=window['sl_{21FEF8D7-4385-4DEB-B34B-7A4BB675EF9A}'];loadHandler&&loadHandler(17, '<div id="spr0_158742c0"><div id="spr1_158742c0" class="kern slide"><img id="img4_158742c0" src="data/img8.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_158742c0" class="kern slide"><div id="spr3_158742c0" style="left:2.875px;"><img id="img0_158742c0" src="data/img34.png" width="720" height="77" alt="Screen Shot 2019-01-23 at 1.28.09 PM.png" style="top:0.111px;"/></div><div id="spr4_158742c0" style="left:-3px;top:74px;"><img id="img1_158742c0" src="data/img35.png" width="726" height="9" alt=""/></div><div id="spr5_158742c0" style="left:14.859px;top:8.392px;"><img id="img2_158742c0" src="data/img36.png" width="164" height="57" alt="GOAL_int-LogoFINAL.pdf" style="left:-0.148px;top:0.246px;"/></div><div id="spr6_158742c0" style="left:190.546px;top:19.014px;"><div style="width:0px;"><span id="txt0_158742c0" data-width="475.675781" style="left:7.2px;top:0.564px;">2017 UPDATE OF ESC/EAS Task Force for PCSK9i</span></div></div><div id="spr7_158742c0" style="left:41.584px;top:488.899px;"><div style="width:0px;"><span id="txt1_158742c0" data-width="529.699219" style="left:7.2px;top:2.082px;">ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CAD, coronary artery disease;</span></div><div style="width:0px;"><span id="txt2_158742c0" data-width="461.572266" style="left:7.2px;top:16.482px;">PAD, peripheral arterial disease; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor</span></div><div style="width:0px;"><span id="txt3_158742c0" data-width="184.634766" style="left:7.2px;top:30.882px;">Landmesser U, et al. Eur Heart J. 2017</span></div></div><div id="spr8_158742c0" style="left:15.649px;top:78.687px;"></div><div id="spr9_158742c0" style="left:11.02px;top:75.673px;"><img id="img3_158742c0" src="data/img39.png" width="696" height="417" alt="" style="left:0.245px;top:0.23px;"/></div></div></div>');})();